Last reviewed · How we verify
FX201
At a glance
| Generic name | FX201 |
|---|---|
| Sponsor | Pacira Pharmaceuticals, Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FX201 CI brief — competitive landscape report
- FX201 updates RSS · CI watch RSS
- Pacira Pharmaceuticals, Inc portfolio CI